Multiple Sclerosis: Diagnosis, Disease Courses, and PT Management

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/394

encourage image

There's no tags or description

Looks like no tags are added yet.

395 Terms

1
New cards

MS: Definition

Autoimmune CNS disease causing inflammatory demyelination and axonal transection; disrupts white-matter conduction.

2
New cards

MS: Diagnostic framework

Dissemination of lesions in space and time, supported by MRI T2 lesions and CSF oligoclonal bands.

3
New cards

MS: Dissemination in space

Evidence of damage in at least 2 separate CNS areas.

4
New cards

MS: Dissemination in time

Evidence of damage at 2 distinct points in time, at least 1 month apart.

5
New cards

MS: Pathophysiology cascade

T-cells cross BBB → oligodendrocyte death → B-cell cytokines → inflammation → demyelination → remyelination → plaque.

6
New cards

MS: Acute inflammatory phase

Focal areas of demyelination and inflammation in CNS white matter.

7
New cards

MS: Chronic phase

Remyelination, inflammation that resolves without repair, or ongoing smoldering activity.

8
New cards

MS: Demyelination

Slows or blocks conduction; function may partially recover.

9
New cards

MS: Axonal transection

Permanent damage that drives long-term disability.

10
New cards

MS: Why heat worsens MS

Poorly myelinated segments conduct marginally; increased body temperature can temporarily worsen symptoms.

11
New cards

MS: Peripheral nerve involvement

MS targets CNS oligodendrocytes/myelin and generally spares peripheral nerves.

12
New cards

MS: Typical age of onset

Young adults, typically ages 20-30.

13
New cards

MS: Sex prevalence

Women are affected more often than men.

14
New cards

MS: US prevalence

About 900,000 people.

15
New cards

MS: Genetic risk

Family clustering and HLA-DRB1*15:01 allele.

16
New cards

MS: Lifestyle/environment risks

Childhood obesity, cigarette smoking, Epstein-Barr virus, and higher latitudes/colder climates.

17
New cards

MS: Common neurologic/motor findings

Optic neuritis, gait and motor deficits, sensory deficits, brainstem syndromes, ataxia, and spasticity.

18
New cards

MS: Other common findings

Fatigue, heat intolerance, cognitive dysfunction, depression, sexual dysfunction, and bowel/bladder issues.

19
New cards

MS: Clinically isolated syndrome (CIS)

Single first episode that does not yet meet dissemination-in-space and -time criteria.

20
New cards

MS: Relapsing-remitting (RRMS)

Relapses followed by recovery to or near baseline; disability is relatively flat between relapses.

21
New cards

MS: Secondary progressive (SPMS)

Begins as RRMS, then transitions to steady worsening.

22
New cards

MS: Primary progressive (PPMS)

Steady worsening from onset without distinct relapses.

23
New cards

MS: Progressive relapsing (PRMS)

Steady worsening from onset with superimposed relapses and stepwise rises.

24
New cards

MS: Most common course at onset

RRMS; about 85% of cases.

25
New cards

MS: PPMS proportion

Roughly 10-15%.

26
New cards

MS: Preventing relapses

Disease-modifying therapies (DMTs).

27
New cards

MS: Treating acute relapses

High-dose systemic steroids.

28
New cards

MS: Symptom management

Address spasticity, fatigue, cognitive dysfunction, and bladder problems.

29
New cards

MS: Lifestyle management

Avoid heat, increase physical activity, and stop smoking.

30
New cards

MS: Prognostic factors

Sex, age, symptoms, disease course, neurologic findings at 5 years, and MRI findings.

31
New cards

MS: Generally favorable prognosis features

Female sex, younger onset, sensory/optic onset, relapsing course, and low MRI lesion load.

32
New cards

MS PT: Four common problem areas

Fatigue, gait/balance deficits, spasticity, and ataxia.

33
New cards

MS PT: ICF framework

Health condition → body function/structure impairment → activity limitation → participation restriction; include environmental and personal factors.

34
New cards

MS EDGE gait measures

MSWS-12, 6-Minute Walk Test (6MWT), and Timed 25-Foot Walk (T25FW).

35
New cards

MS EDGE balance measures

Berg Balance Scale, Dizziness Handicap Inventory (DHI), and cognitive/manual dual-task TUG.

36
New cards

MS EDGE UE dexterity measure

9-Hole Peg Test.

37
New cards

MS EDGE quality-of-life measures

MS Impact Scale (MSIS-29) and MS Quality of Life-54 (MSQoL-54).

38
New cards

MS Functional Composite

Combines T25FW, 9-Hole Peg Test, and a cognitive processing test (PASAT).

39
New cards

FSMC

20-item self-report measure of motor and cognitive fatigue in MS; free.

40
New cards

MFIS

21-item measure of fatigue impact on physical, cognitive, and psychosocial function over the past 4 weeks; costs money.

41
New cards

MS spasticity measures

No MS EDGE recommendation; use Modified Ashworth Scale (MAS) or Tardieu.

42
New cards

MS ataxia tests

No MS EDGE recommendation; use finger-to-nose, heel-to-shin, and dysdiadochokinesia.

43
New cards

Tardieu vs MAS

Tardieu tests at multiple speeds and better separates velocity-dependent spasticity from contracture.

44
New cards

MS PT treatment considerations

Heat can worsen weakness/fatigue; medications may add fatigue; inactivity causes deconditioning/obesity; depression and sleep disruption are common.

45
New cards

MS PT goals

Optimize independence, safety, quality of life, activity, and respiratory function; provide equipment, community resources, and education.

46
New cards

MS FES evidence

May provide an orthotic effect, improve gait quality, and reduce falls; studies did not consistently improve walking speed or endurance.

47
New cards

MS endurance training evidence

Can improve mobility, depression, fatigue, cognitive function, strength, and anxiety.

48
New cards

MS progressive resistance evidence

24 weeks/48 sessions improved strength and physical/neuromuscular function; one study found increased cortical thickness.

49
New cards

MS inspiratory muscle training

Compared with deep breathing, improved maximal inspiratory and expiratory pressures.

50
New cards

MS BWSTT/RAGT evidence

Studies found improvements in walking speed, endurance, double-limb support, disability, and/or 6MWT; RAGT may reduce fall risk during training.

51
New cards

MS TENS evidence

Improved gastrocnemius EMG activity and tone, reduced spasms, and reduced central pain.

52
New cards

MS tDCS evidence

Improved mood, cognitive processing speed, fatigue, and pain.

53
New cards

MS focal muscle vibration

May improve gait by reducing spasticity; also associated with less pain and better quality of life.

54
New cards

Balance sensory systems

Vestibular, visual, and somatosensory input are integrated by the brainstem, cerebellum, and cerebral cortex.

55
New cards

Vestibular input

Provides equilibrium, spatial awareness, rotation, and linear-movement information.

56
New cards

Visual input

Provides sight for balance and orientation.

57
New cards

Somatosensory input

Provides proprioception and touch information.

58
New cards

Brainstem role in balance

Integrates and sorts sensory information.

59
New cards

Cerebellum role in balance

Coordinates and regulates posture, movement, and balance.

60
New cards

Vestibulo-ocular reflex (VOR)

Controls eye movement to stabilize gaze during head movement.

61
New cards

Vestibulospinal pathways

Produce postural adjustments.

62
New cards

Vestibular dysfunction prevalence

Up to 35% of US adults age 40+ (about 69 million) have experienced dysfunction.

63
New cards

Dizziness in adults 65+

About 80% have experienced dizziness.

64
New cards

BPPV prevalence

Most common vestibular disorder; causes about 50% of dizziness in older adults.

65
New cards

Vestibular diagnosis pathway

Patients see an average of 4-5 physicians before diagnosis.

66
New cards

Vestibular rehabilitation therapy (VRT)

Exercise-based program to reduce vertigo/dizziness, improve gaze stability, and reduce imbalance and falls.

67
New cards

Peripheral vestibular causes

BPPV, vestibular neuritis, labyrinthitis, Meniere disease, vestibular neuroma, and superior canal dehiscence/fistula.

68
New cards

Central dizziness causes

Brainstem/cerebellar stroke, concussion, TBI/diffuse axonal injury, and migraine.

69
New cards

Non-vestibular dizziness causes

Cervicogenic dizziness, orthostatic hypotension, vertebral artery insufficiency, hypoglycemia, and psychiatric causes.

70
New cards

Vestibular neuritis vs labyrinthitis

Neuritis affects the vestibular nerve without hearing loss; labyrinthitis involves the labyrinth and may include hearing loss.

71
New cards

History framework for dizziness

Assess tempo, symptoms, and circumstances.

72
New cards

Acute dizziness

Symptoms lasting 3 days or less.

73
New cards

Chronic dizziness

Symptoms lasting more than 3 days.

74
New cards

Episodic dizziness

Spells lasting seconds, minutes, or hours.

75
New cards

Vertigo

Illusion of movement of self or environment, often spinning, from imbalance of neural activity.

76
New cards

Disequilibrium

Imbalance or unsteadiness while standing or walking; may reflect visual, vestibular, or proprioceptive deficits.

77
New cards

Lightheadedness

Feeling faint or about to pass out, often from temporarily reduced cerebral blood flow.

78
New cards

Motion sickness

Dizziness, fatigue, pallor, sweating, nausea, and sometimes vomiting during passive locomotion from visual-vestibular mismatch.

79
New cards

Oscillopsia

Objects appear to bounce in the visual field; usually associated with bilateral vestibular loss.

80
New cards

Mal de debarquement

Rocking/swaying sensation that can persist for days after a long sea or air trip.

81
New cards

Visual motion sensitivity

Dizziness provoked by full-field moving or patterned visual stimuli; usually central dysfunction.

82
New cards

Common visual symptoms in vestibular patients

Blurred/double vision and light sensitivity.

83
New cards

Common auditory symptoms in vestibular patients

Hearing loss, difficulty hearing, ear fullness, or sound sensitivity.

84
New cards

BPPV history clue

Room spins with sudden head movement, especially rolling or turning in bed; brief true vertigo.

85
New cards

Bilateral vestibular hypofunction history clue

Oscillopsia and constant imbalance.

86
New cards

Unilateral vestibular hypofunction history clue

Dizziness with head turns or turning around while standing.

87
New cards

Orthostatic hypotension history clue

Dizziness when standing up, especially first thing in the morning.

88
New cards

Central dysfunction history clue

Visual motion sensitivity, often after concussion/TBI or with other central pathology.

89
New cards

Vestibular history: circumstances

Ask about standing after lying, lying/sitting up, turning in bed, bending, looking up, exertion, or spontaneous symptoms.

90
New cards

Other vestibular history items

Falls, ADL impact/avoidance, patient beliefs, headaches/migraines, neck/joint pain, and medications.

91
New cards

Vestibular exam: usual first step

Begin with the oculomotor examination unless history strongly suggests BPPV.

92
New cards

Vestibular exam: BPPV exception

If history suggests BPPV, perform positional testing first because BPPV can make other vestibular/oculomotor findings inaccurate.

93
New cards

Ambient light testing

Allows visual fixation.

94
New cards

Frenzel/infrared goggles

Blur or remove fixation to reveal peripheral nystagmus.

95
New cards

Why goggles are used

Visual fixation suppresses peripheral nystagmus; central nystagmus is not suppressed and may be visible in room light.

96
New cards

Peripheral vs central spontaneous nystagmus

Peripheral nystagmus may appear only with fixation removed; spontaneous nystagmus in room light with other central signs warrants medical referral.

97
New cards

Oculomotor central tests

Smooth pursuit, saccades, vergence/convergence, and VOR cancellation.

98
New cards

Normal smooth pursuit

Smooth tracking with minimal symptoms.

99
New cards

Abnormal smooth pursuit

Delays or saccadic intrusions; may indicate central dysfunction.

100
New cards

Normal saccades

Target reached in 1-2 eye movements with minimal symptoms.